Stryker Corp

Explore how Stryker Corp’s leadership change, value‑based reimbursement, and robotics innovation affect its market position and investor outlook.

Citigroup keeps a buy rating on Stryker, citing robust leadership plans and a diversified product pipeline that could drive earnings growth and lower device costs.

Explore Stryker Corp’s strong 13.8% annual returns, rising organic sales, and $2.1 billion R&D push, while weighing regulatory, supply‑chain, and biologics risks.

Discover how Stryker’s Q3 earnings beat expectations, driving margin growth and tech adoption, and what that means for investors and the future of medical device innovation.

Stryker Corporation’s stock price and valuation metrics, including a high price-to-earnings ratio and price-to-book ratio, indicate a premium valuation of the medical technology company.

Stryker Corporation’s stock price has fluctuated significantly over the past 52 weeks, with a current price of $394.22, and valuation multiples indicating a premium value on the company’s earnings and assets.

Stryker Corporation has announced a quarterly dividend of $0.84 per share, effective August 7.

Stryker Corp has announced a quarterly dividend of $0.84 per share, maintaining its history of regular dividend payments despite the overall healthcare sector’s 5% decline this year.

Stryker Corp has announced a quarterly dividend of $0.84 per share and released its Q2 2025 earnings call transcript, amidst a 5% decline in the US healthcare sector.

Stryker Corp’s stock price has plummeted despite reporting a record profit, raising questions about the company’s ability to translate financial success into market momentum.